UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002845 |
|---|---|
| Receipt number | R000003450 |
| Scientific Title | Phase I Trial of S-1 and Weekly Oxaliplatin in Combination with Radiotherapy for Neoadjuvant Therapy of Locally Advanced Rectum Cancer |
| Date of disclosure of the study information | 2009/12/04 |
| Last modified on | 2015/09/19 14:50:47 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I Trial of S-1 and Weekly Oxaliplatin in Combination with Radiotherapy for Neoadjuvant Therapy of Locally Advanced Rectum Cancer
Acronym
SOX-RT(P-I)
Scientific Title
Phase I Trial of S-1 and Weekly Oxaliplatin in Combination with Radiotherapy for Neoadjuvant Therapy of Locally Advanced Rectum Cancer
Scientific Title:Acronym
SOX-RT(P-I)
Region
| Japan |
Condition
Condition
Rectal cancer of Stage II or III with T4 or lateral lymph node metastasis at the pre-operative diagnosis
Classification by specialty
| Gastroenterology | Gastrointestinal surgery | Radiology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To determine dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD), and identify a feasible oxaliplatin dose for combination therapy of S-1 and concurrent radiation against stage II or III distal rectal cancer with T4 or lateral lymph node metastasis.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Phase I
Assessment
Primary outcomes
the MTD and RD of oxaliplatin
Key secondary outcomes
Adverse events, radiologic and pathologic tumor response, surgical morbidity
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine | Maneuver |
Interventions/Control_1
1)S-1 at a dose of 80mg/m2/day orally in 2 divided doses for 5 days a week during radiotherapy
2) Weekly oxaliplatin at a dose of 40-60mg/m2 intravenously
3) Radiotherapy is delivered a total irradiation dose of 50.4 Gy given in daily fractions of 1.8 Gy, 5 days a week and additional exposure for 3 times.
4) Surgery
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.Histologically confirmed Rectum cancer (adenocarcinoma, mucinous carcinoma, signet-ring cell carcinoma, adenosquamous carcinoma)
2. Preoperative findings (Must meet all the conditions)
i.Main lesion of the tumor is located at the Rs, Ra, Rb, or P
ii. Lower tumor margin is below the peritoneal reflection
iii. With lateral LN metastasis (internal iliac lymph nodes, obturator lymph nodes or common iliac lymph nodes (Shorter diameter of LN is less than 10 mm or more by pelvic CT or MRI)), or T4
3. No evidence of distant metastasis
4. age:20-75years old
5. ECOG PS:0 or 1
6. With or without target lesion by RECIST
7. Without prior anti-cancer therapy
8. Adequate oral intake
9. Adequate organ function
10.Written IC
Key exclusion criteria
1. Suspected metastasis of external iliac lymph nodes, para-aortic lymph nodes, or inguinal lymph nodes by pelvic MRI.
2. Prior or synchronous invasive malignancy (expect carcinoma in situ or superficial carcinoma which is able to eradicate by local therapy) unless disease free for a minimum of 5 years
3. Evidence of active bacterial or fungal infection (existing fever above 38 degrees centigrade due to infection)
4. Previous history of severe drug-induced allergy
5. Need to treatment with flucytosine, atazanavir sulfate, or warfalin
6. Need systemic administration of corticosteroids
7. Evidence of positive hepatitis B virus surface antigen
8. Evidence of severe watery diarrhea
9. Evidence of uncontrolled diabetic mellitus
10. Evidence of uncontrolled hypertension
11. Need to intervention for heart disease according to the findings of electrocardiogram within the last 28 days
12. Myocardial infarction or unstable angina pectoris within the last 12 months
13. Major surgery within 4 weeks of study enrollment (other than diverting colostomy)
14. Severe comorbidity (ie, bowel paralysis, bowel obstruction, interstitial pneumotitis, pulmonary fibrosis, advanced emphysema, heart disease which is difficult to manage, renal failure, hepatic failure)
15. Pregnant or lactating and woman with childbearing potential who lacked effective contraception
16. Evidence of psychiatric disability interfering with enrollment to clinical trial
17.Patients judged inappropriate for this study by the physicians
Target sample size
12
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masayuki Ohue |
Organization
Osaka Medical Center for Cancer and Cardiovascular Diseases
Division name
Department of Surgery
Zip code
Address
1-3-3 Nakamichi, higashinari-ku, Osaka City, Osaka Prefecture
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masayuki Ohue |
Organization
Osaka Medical Center for Cancer and Cardiovascular Diseases
Division name
Department of Surgery
Zip code
Address
TEL
Homepage URL
ohue-ma@mc.pref.osaka.jp
Sponsor or person
Institute
National cancer center hosital
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 12 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2009 | Year | 11 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 12 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 05 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2009 | Year | 12 | Month | 03 | Day |
Last modified on
| 2015 | Year | 09 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003450
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
